GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically meaningful overall survival trend observed at interim analysis Results presented in same-day presentations at ESMO Virtual Plenary and SGO Annual Meeting and simultaneously published in The New England Journal of Medicine Regulatory submissions planned for the first half of 2023 LONDON , March 27, 2023 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK said: "These positive results from the RUBY trial bring us one step closer to addressing the significant unmet needs of endometrial cancer patients and add to the growing body of evidence on dostarlimab-gxly, strengthening our belief in its potential to transform cancer treatment as a backbone immuno-oncology therapy.

Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

Leggett & Platt

LyondellBasell Industries

Altria

AT&T

Verizon

I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. This month, I went heavier than I normally do, deploying over $3,000.

Recent Stock Purchase March 2023

A California judge will allow expert testimony linking GSK's heartburn drug Zantac to cancer. The decision took a bite out of GSK stock Friday.

GSK Stock Skids On Judge's New Ruling As Zantac Trial Looms

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 3.6% after it said it "respectfully disagrees" with a ruling by a California state court in litigation related to claims that the company's former heartburn drug, Zantac, caused cancer. Yesterday's ruling was made in a ‘Sargon' hearing, a state-specific legal decision on the admissibility of expert opinion, where the ruling related to whether California resident James Goetz's experts can testify at trial as part of the claim he has brought.

GSK falls after Zantac expert opinion ruling in California litigation

U.K. pharmaceutical giant GSK on Friday said it disagreed with a California state court ruling on Zantac, or ranitidine, and its links with cancer. “Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer,” the pharmaceutical said.

GSK says it disagrees with California state court ruling on Zantac

Aviva PLC

Barclays

British American Tobacco

HSBC Holdings

Imperial Brands PLC

Legal & General Group PLC

Lloyds Banking Group

National Grid

NatWest Group plc 

Rio Tinto plc Sponsored

Much has changed since the last update in September, with banks now hogging many of the top spots. Bank shares have gone down in the last couple of weeks and their dividend yields have gone up, because several banks have recently failed.

Top 40 High-Yield Blue-Chip U.K. Stocks: Spring 2023

Vertex Pharmaceuticals

vTv Therapeutics

When it comes to finding good pharma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ultimate key catalyst for stocks, and it's much easier for companies to generate gigantic profits if there is a huge demand for the products they are developing.

3 Pharma Stocks That Could Benefit from Global Healthcare Trends

Moderna

Pfizer

The vaccine's revenue would help Pfizer make up for looming patent cliffs. GSK's annual financials were the healthiest of the three companies.

Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

GSK PLC (LSE:GSK, NYSE:GSK)'s shares jumped 1.8% in early exchanges in London supported by an upgrade by Deutsche Bank. The German investment bank has put the FTSE 100-listed pharma giant on its ‘buy' list (previously hold) and increased its price target by 13% to 1,700p.

GSK rises as Deutsche upgrades to buy with 1,700p target

GSK launches national health education campaign, Sideline RSV, to highlight risk of Respiratory Syncytial Virus (RSV).

GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults

GSK PLC (LSE:GSK, NYSE:GSK) has announced positive results from its phase III trial of its MenABCWY combination vaccine candidate in meningococcal, a major cause of meningitis and septicaemia. The drug, a five-in-one amalgam of treatments, was administered in two doses given six months apart.

GSK scores phase III success with meningococcal disease vaccine

W. P. Carey

In the current economic climate of rising interest rates, persistent inflation, simmering geopolitical risks and looming recessionary threats, it's crucial to prioritize quality, safety and high dividends when selecting stocks. This article explores three high dividend stocks with appealing total return potential.

3 High Dividend Stocks With Attractive Total Return Potential

GSK's RSV vaccine candidate could prevent deaths and hospitalizations in older patients. The product could end up generating over $1 billion in annual revenue for the company.

Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?

2023 is flying by as two months are already in the books and that fact simply highlights to me the importance of staying invested in the stock market during the good times and bad. VZ stock is trading with a low forward PE of just over 8 and sports a very juicy yield getting close to 7% and a moderate payout ratio of around 51% making this dividend appear to be very safe going forward.

March 2023 Stock Considerations

GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine has been endorsed by advisors to the US Food & Drug Administration, who assessed its safety and efficacy in older adults. The decision puts GSK in direct competition with Pfizer Inc (NYSE:PFE), which has also developed a promising RSV vaccine.

GSK neck and neck with Pfizer in the race to get first RSV jab to market

Haleon PLC

Haleon , the world's biggest standalone consumer health business with brands such as Sensodyne toothpaste and Advil painkillers, on Thursday forecast 4-6% organic revenue growth in 2023.

GSK spinoff Haleon forecasts 4-6% revenue growth in 2023

A panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc's respiratory syncytial virus (RSV) vaccine, setting it up for a race with rival Pfizer to become the first approved U.S. shot against the disease.

US panel backs GSK vaccine, heating up RSV vaccine race

The Food and Drug Administration's independent panel of advisors on Wednesday recommended GlaxoSmithKline's RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over nervous system disorders that may be tied to the shot.

FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks

AbbVie

Alvotech SA

Amgen

Bristol-Myers

Coherus BioSciences

Cigna

CVS Health

Fresenius Medical Care

Johnson & Johnson

Merck

Novo Nordisk

Novartis

Organon & Co

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Teva Pharmaceutical

Viatris

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

Cardinal Health

Chubb

Embecta Corp

General Electric

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Mondelez

PepsiCo

Philip Morris

Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. The market may move up and down irrationally and seemingly on a whim while our dividends remain much more stable, reliable, and predictable.

Dividend Income Update: January 2023

Bank of Nova Scotia

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Iron Mountain

MDU Resources Group

Medical Properties Trust

NetApp

Realty Income Corp

Orion Office REIT

Paramount Global

Invesco S&P 500 High Dividend Low Volatility ETF

TotalEnergies SE

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. Dividend Income is the fruit from the labor of investing your money in the stock market.

Dividend Income Summary: Lanny's January 2023 Summary

GSK PLC (LSE:GSK, NYSE:GSK) said that the US Food and Drug Administration (FDA) has granted full approval for Jemperli, a drug for the treatment of mismatch repair-deficient endometrial cancer in adult patients. The approval comes after the successful results from the GARNET phase I trial, which demonstrated an overall response rate of 45.4%.

GSK cancer drug gets the FDA green light

Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4% 85.9% of patients had duration of response ≥12 months and 54.7% of patients had duration of response ≥24 months LONDON , Feb. 10, 2023 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: "This US regulatory action confirms our confidence in Jemperli as an important treatment option for patients with dMMR recurrent or advanced endometrial cancer.

US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer

Exact Sciences

Gilead Sciences

Immunocore Holdings

Eli Lilly

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

News for GlaxoSmithKline Stock (GSK)